EFFECT OF INTRAVENOUS ANTI-IL5 (MEPOLIZUMAB) IN HYPEREOSINOPHILIC SYNDROMES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是评估抗IL-5在18-24名高嗜酸性粒细胞增多症(HES)患者中的安全性，并确定研究药物对高嗜酸性粒细胞综合征(血液或组织中特定类型的白细胞数量较高)的治疗效果(好或坏)。4组6人将接受抗IL-5治疗。A组和B组是安全组，在输液期间接受抗IL-5治疗，而不改变他们目前使用的HES药物。C组将接受药物治疗，而他们目前的HES药物(泼尼松等)将在研究结束时减少25%。D组将遵循同样的做法，目前的HES药物最高可减少50%。这项研究的主要结果指标是该人群的安全性和外周血嗜酸性粒细胞水平和/或组织嗜酸性粒细胞水平的降低。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to assess the safety of anti IL-5 in 18-24 patients with hypereosinophilia (HES) and determine what effect (good or bad) the study medication has on the management of hypereosinophilic syndromes (high number of a particular kind of white blood cell in the blood or in the tissues).¿ 4 groups of 6 individuals will receive Anti IL-5. Groups A and B are safety groups, receiving anti IL-5 with out changes to their current HES medications during infusions. Group C will receive the drug while their current HES medication ( prednisone, etc) would be reduced up to 25% by end of the study. Group D will follow do the same with up to 50% reduction in Current HES medication. Primary outcome measures for this study are safety in this population and reduction of Peripheral blood eosinophil levels and/ or tissue eosinophil level.